Abstract
BACKGROUND. Acute myelogenous leukemia (AML) associated with core-binding-factor (CBF) abnormalities is the type of leukemia most responsive to cytarabine (ara-C) therapy and is of relative favorable prognosis. In vitro and ex vivo observations suggest that increases in intracellular ara-C levels influenced by administration of fludarabine and granulocyte colony-stimulating factor (GCSF) increase the effect of ara-C, prompting us to clinically evaluate the efficacy of such combinations. METHODS. We analyzed the event-free survival of patients with newly diagnosed CBF AML treated with fludarabine and ara-C (FA) (N = 45) or with FA and GCSF (FLAG) (N = 22) and compared results to patients treated with regimens consisting of idarubicin and ara-C with or without GCSF (IA/IAG) (N = 47). RESULTS. After accounting for prognostic covariates other than treatment (including year in which treatment was administered), FA, and in particular FLAG, were associated with longer event-free survival than IA/IAG. CONCLUSIONS. Thus, our data lends clinical credence to the observed modulation of ara-C by fludarabine and GCSF.
Original language | English (US) |
---|---|
Pages (from-to) | 3181-3185 |
Number of pages | 5 |
Journal | Cancer |
Volume | 113 |
Issue number | 11 |
DOIs | |
State | Published - Dec 1 2008 |
Keywords
- Ara-C
- Core-binding-factor
- Fludarabine
- GCSF
ASJC Scopus subject areas
- Oncology
- Cancer Research